Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EEF1A2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EEF1A2 Recombinant Protein (Full-Length) | |
| High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified; theoretical MW confirmed by SDS-PAGE. HEK293 expressed (proper post-translational modifications). | View EEF1A2 Products | |
| Paralog Counter-Screen | EEF1A1 Recombinant Protein | |
| For selectivity assays against the ubiquitous paralog. >95% purity, sequence verified. | View EEF1A1 Products | |
| Gene Delivery | EEF1A2 Premade Lentivirus | |
| CMV promoter-driven full-length ORF; high titer (>10^8 TU/mL); puromycin selection. For stable cell line construction. | View EEF1A2 Products | |
| Benchmark Ab | Anti-EEF1A2 (Paralog-Specific) Recombinant Antibody | |
| Validated for WB/IP. Distinguishes EEF1A2 from EEF1A1 by differential peptide mapping. | View EEF1A2 Products | |
| Validator | EEF1A2 siRNA Set | |
| Three unique target sequences for isoform-specific knockdown; includes negative control siRNA. | View EEF1A2 Products | |
| Related Target | KRAS | |
| Oncogenic driver in PDAC; synthetic lethality and co-targeting rationale with EEF1A2. | View KRAS Products | |
| Related Target | MYC | |
| Convergent translation machinery dependency; pathway partner for combination strategy. | View MYC Products | |
| Pathway Partner | EEF2 | |
| Downstream elongation factor; for combination studies in translation-targeted therapies. | View EEF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (EEF1A2 vs. EEF1A1) | Paired recombinant human proteins (EEF1A2 & EEF1A1) available with >95% purity; distinct C-terminal sequences enable paralog-specific assay design. |
| Intracellular Target Engagement | High-titer Lentivirus for stable overexpression in cancer cell lines (e.g., PDAC, ovarian); suitable for PPI and localization studies. |
| Solubility & Conformation | HEK293-expressed proteins preserve phosphorylation sites and native folding, outperforming E. coli alternatives. |
| Mechanism-of-Action Validation | EEF1A2 siRNA Set included for loss-of-function specificity controls in proliferation and translation assays. |
| False Positives / Off-target Binding | Anti-EEF1A2 benchmark antibody with paralog-discriminating epitope; sequence-verified recombinant production. |
Live EEF1A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
EEF1A2 has emerged as a validated oncogenic driver in pancreatic ductal adenocarcinoma (PDAC), ovarian serous carcinoma, breast cancer, and lung adenocarcinoma, correlating with poor survival. Beyond oncology, EEF1A2 de novo missense mutations (e.g., G70S, D252H, and those reported in DEE33 and MRD38) cause severe neurodevelopmental disorders including epileptic encephalopathy and Rett-like phenotypes, creating a dual-front clinical opportunity. The most advanced eEF1A-targeted agent, Plitidepsin (PharmaMar), has been evaluated in multiple myeloma and COVID-19, while next-generation R&D is shifting from generic translational inhibitors to isoform-specific antisense oligonucleotides (ASOs), targeted protein degradation (PROTACs), and small-molecule disruptors of non-canonical protein–protein interactions (e.g., actin binding). Synthetic lethal combinations with KRAS-mutant backgrounds and allele-specific therapies for rare CNS mutations represent the frontier of innovation. Early academic and biotech players dominate this nascent space, with no clinical-stage candidates beyond Phase I, signaling a critical window for first-in-class development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (GTP-site / Plitidepsin) | PharmaMar; Emerging Academic Labs | Multiple Myeloma, Solid Tumors (Pancreatic, Ovarian) | Thermal Shift Assay / DSF; selectivity assay against EEF1A1 using paired recombinant proteins |
| PROTAC / Degrader | Early Stage Biotechs (Arvinas-type) | Refractory Solid Tumors | Ternary complex validation; cell permeability models; E3 ligase recruitment assays |
| ASO / siRNA | Ionis, Alnylam (Academic partnerships) | PDAC, Ovarian, Epileptic Encephalopathy | Isoform-specific knockdown validation; qPCR & protein standards for EEF1A2 vs EEF1A1 |
| PPI Inhibitor (Actin-binding) | Biotech Startups | Metastatic Cancers | SPR/BLI with EEF1A2 vs EEF1A1 selectivity panels; cell-based co-localization assays |